Percheron Therapeutics Ltd (PER) - Total Assets
Based on the latest financial reports, Percheron Therapeutics Ltd (PER) holds total assets worth AU$12.44 Million AUD (≈ $8.80 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Percheron Therapeutics Ltd (PER) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Percheron Therapeutics Ltd - Total Assets Trend (2001–2025)
This chart illustrates how Percheron Therapeutics Ltd's total assets have evolved over time, based on quarterly financial data. See Percheron Therapeutics Ltd book value and equity for net asset value and shareholders' equity analysis.
Percheron Therapeutics Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Percheron Therapeutics Ltd's total assets of AU$12.44 Million consist of 99.7% current assets and 0.3% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 81.8% |
| Accounts Receivable | AU$1.58 Million | 12.7% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$0.00 | 0.0% |
| Intangible Assets | AU$0.00 | 0.0% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2001–2025)
This chart illustrates how Percheron Therapeutics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see PER stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Percheron Therapeutics Ltd's current assets represent 99.7% of total assets in 2025, an increase from 68.1% in 2001.
- Cash Position: Cash and equivalents constituted 81.8% of total assets in 2025, up from 68.1% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 31.0% in 2001.
- Asset Diversification: The largest asset category is accounts receivable at 12.7% of total assets.
Percheron Therapeutics Ltd Competitors by Total Assets
Key competitors of Percheron Therapeutics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Alkem Laboratories Limited
NSE:ALKEM
|
India | Rs202.87 Billion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥31.82 Billion |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.64 Billion |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623
|
China | CN¥35.27 Billion |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436
|
China | CN¥1.41 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Zhejiang Medicine Co Ltd
SHG:600216
|
China | CN¥14.18 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
Percheron Therapeutics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.10 | 2.81 | 6.53 |
| Quick Ratio | 5.10 | 2.81 | 6.27 |
| Cash Ratio | 0.00 | 0.00 | 5.08 |
| Working Capital | AU$9.97 Million | AU$9.32 Million | AU$4.42 Million |
Percheron Therapeutics Ltd - Advanced Valuation Insights
This section examines the relationship between Percheron Therapeutics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.87 |
| Latest Market Cap to Assets Ratio | 0.19 |
| Asset Growth Rate (YoY) | -14.4% |
| Total Assets | AU$12.44 Million |
| Market Capitalization | $2.31 Million USD |
Valuation Analysis
Below Book Valuation: The market values Percheron Therapeutics Ltd's assets below their book value (0.19x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Percheron Therapeutics Ltd's assets decreased by 14.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Percheron Therapeutics Ltd (2001–2025)
The table below shows the annual total assets of Percheron Therapeutics Ltd from 2001 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$12.44 Million ≈ $8.80 Million |
-14.41% |
| 2024-06-30 | AU$14.53 Million ≈ $10.28 Million |
+13.14% |
| 2023-06-30 | AU$12.84 Million ≈ $9.09 Million |
-42.76% |
| 2022-06-30 | AU$22.44 Million ≈ $15.88 Million |
+220.50% |
| 2021-06-30 | AU$7.00 Million ≈ $4.95 Million |
+30.80% |
| 2020-06-30 | AU$5.35 Million ≈ $3.79 Million |
+44.71% |
| 2019-06-30 | AU$3.70 Million ≈ $2.62 Million |
-22.98% |
| 2018-06-30 | AU$4.80 Million ≈ $3.40 Million |
+89.13% |
| 2017-06-30 | AU$2.54 Million ≈ $1.80 Million |
-52.34% |
| 2016-06-30 | AU$5.33 Million ≈ $3.77 Million |
-30.57% |
| 2015-06-30 | AU$7.67 Million ≈ $5.43 Million |
+188.89% |
| 2014-06-30 | AU$2.66 Million ≈ $1.88 Million |
-48.93% |
| 2013-06-30 | AU$5.20 Million ≈ $3.68 Million |
-8.58% |
| 2012-06-30 | AU$5.69 Million ≈ $4.03 Million |
+133.56% |
| 2011-06-30 | AU$2.44 Million ≈ $1.72 Million |
+34.17% |
| 2010-06-30 | AU$1.82 Million ≈ $1.28 Million |
-63.61% |
| 2009-06-30 | AU$4.99 Million ≈ $3.53 Million |
-49.43% |
| 2008-06-30 | AU$9.87 Million ≈ $6.98 Million |
+22.56% |
| 2007-06-30 | AU$8.05 Million ≈ $5.70 Million |
-11.70% |
| 2006-06-30 | AU$9.12 Million ≈ $6.45 Million |
-18.76% |
| 2005-06-30 | AU$11.22 Million ≈ $7.94 Million |
-38.17% |
| 2004-06-30 | AU$18.15 Million ≈ $12.84 Million |
+51.48% |
| 2003-06-30 | AU$11.98 Million ≈ $8.48 Million |
-21.86% |
| 2002-06-30 | AU$15.33 Million ≈ $10.85 Million |
-23.67% |
| 2001-06-30 | AU$20.09 Million ≈ $14.21 Million |
-- |
About Percheron Therapeutics Ltd
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals for cancer and rare diseases in Australia. The company's lead asset is ATL1102, an antisense oligonucleotide inhibitor of CD49d, which is in Phase IIb clinical trial for the treatment of Duchenne muscular dystrophy, multiple sclerosis, asthma, and other inflammatory indications. It also devel… Read more